Drugs / Ad4-H5-vaccination-oral route
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT01443936 | Sep 2011 → Apr 2018 | avian influenza | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Ad4-H5-vaccination-oral route | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01443936 ↗ |
| Known as | Ad4-H5-Vtn | “This is a Phase 1 randomized, single center, dose-escalation study designed to evaluate the safety and immunogenicity of live, replication competent recombinant Adenovirus type...” NCT01443936 ↗ |
| Route | Oral | “The oral enteric-coated capsule will also be assessed in 10 outpatients using similar blood sampling for comparison.” NCT01443936 ↗ |